quantisnow
FeedTopReportsPricing
⌘K
Live feed
08:00:00·66d
PRRelease
Cue Biopharma Inc. logo

Cue Biopharma Announces Preclinical Safety and Tolerability Data for CUE-401 for the Treatment of Autoimmune and Inflammatory Diseases

CUE· Cue Biopharma Inc.
Health Care
Original source

Companies

  • CUE
    Cue Biopharma Inc.
    Health Care

Recent analyst ratings

  • Mar 13UpdateJefferies$6.00
  • Jun 26UpdateOppenheimer$10.00
  • Nov 21UpdatePiper Sandler$7.00
  • Jan 13UpdateH.C. Wainwright$20.00
  • Jan 3UpdateCraig Hallum$28.00

Related

  • SEC2d
    Cue Biopharma Inc. filed SEC Form 8-K: Material Modification to Rights of Security Holders, Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits
  • PR2d
    Cue Biopharma Announces 1-for-30 Reverse Stock Split
  • PR9d
    Cue Biopharma to Present New Preclinical Data on Lead Autoimmune and Inflammatory Disease Candidate CUE-401 at IMMUNOLOGY2026
  • SEC10d
    Cue Biopharma Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders
  • INSIDER13d
    SEC Form 4 filed by Warren Lucinda
  • INSIDER13d
    SEC Form 4 filed by Sandercock Colin
  • INSIDER13d
    SEC Form 4 filed by Baker Daniel G.
  • PR16d
    Cue Biopharma to Receive $7.5 Million Preclinical Milestone Payment from Boehringer Ingelheim Collaboration and License Agreement
quantisnow

Real-time market intelligence for retail investors. Press releases, filings, ratings, and insider flow - all in one stream.

All systems operational

Feeds

Press releasesAnalyst ratingsInsider tradingFDASECRSS feeds

Top lists

TrendingBy market capActive companiesAnalyst upgradesInsider purchasesFDA approvalsSEC filingsSectorsMarket reports

Company

AboutPricingPublish with usContact

Legal

Terms of usePrivacy policyCookie policy

© 2026 quantisnow.com · Democratizing insights since 2022